Nexsen advances kidney diagnostics program
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Nexsen Limited provides an update on its kidney diagnostics program, focusing on its proprietary RenalSure® test for Acute Kidney Injury (AKI). The company is progressing towards a targeted FDA submission for RenalSure® in the near future and has initiated a feasibility study with GENSPEED for a complementary AKI test. This initiative aims to address a significant clinical need in intensive care, where rapid diagnosis of AKI is crucial for patient outcomes.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Nexsen
- Co Secretary Appoint/Resign and Change of Registered Address
- ISO 13485 Certification brings StrepSure closer to market
- Quarterly Report - Q1 FY27
- Notice of AGM and Meeting Materials
- Professor Shekhar Kumta appointed Executive Director
Follow Nexsen into a list and get an email when it puts out news.
Follow Nexsen